活化粒细胞与炎症细胞因子信号驱动T细胞淋巴瘤进展及疾病症状
研究探讨炎症性粒细胞与活化细胞因子信号在滤泡辅助性T细胞型外周T细胞淋巴瘤(TFH-PTCL)疾病进展和症状中的作用。ITK-SYK驱动的小鼠PTCL和原代人TFH-PTCL异种移植物均诱导小鼠炎症,包括中性粒细胞扩增和大量细胞因子释放。粒细胞/淋巴瘤相互作用由干扰素γ(恶性CD4+ T细胞)和白细胞介素6(活化粒细胞)的正性自调节细胞因子环路介导,最终诱导两类细胞广泛的JAK活化。通过抗体(Ly6G)、遗传性粒细胞清除或微环境细胞IL-6缺失阻断炎症症状、减少淋巴瘤浸润并提高小鼠生存;非选择性JAK抑制剂鲁索替尼抑制多种PTCL小鼠模型的TCL进展和粒细胞活化。结果支持粒细胞驱动的炎症、细胞因子诱导的粒细胞/CD4+ TCL相互作用及完整JAK/STAT信号通路对TFH-PTCL发生的重要作用,并支持广泛JAK抑制作为早期疾病阶段的有效治疗策略。
要点
- TFH-PTCL小鼠模型和原代人异种移植物均诱导中性粒细胞扩增和大量细胞因子释放。
- 干扰素γ(恶性CD4+ T细胞)与IL-6(活化粒细胞)形成正性自调节环路,诱导两类细胞JAK1/2/3和TYK2活化。
- 抗体或遗传性粒细胞清除或微环境IL-6缺失可阻断炎症症状、减少淋巴瘤浸润并提高小鼠生存。
核心结论
- 粒细胞驱动的炎症、细胞因子诱导的粒细胞/CD4+ TCL相互作用及完整JAK/STAT信号通路对TFH-PTCL发生具有重要作用。
- 广泛JAK抑制可能是早期疾病阶段的有效治疗策略。
研究设计与样本
- 研究采用ITK-SYK驱动的小鼠PTCL模型和原代人TFH-PTCL异种移植物模型。
- 在多种PTCL小鼠模型中测试了粒细胞清除(Ly6G抗体、LyzM-Cre/MCL1flox/flox遗传清除)和微环境细胞IL-6缺失。
- 在多种PTCL小鼠模型中测试了非选择性JAK抑制剂鲁索替尼。
主要发现
- ITK-SYK驱动的小鼠PTCL和原代人TFH-PTCL异种移植物均诱导小鼠炎症,包括小鼠中性粒细胞扩增和大量细胞因子释放。
- 粒细胞/淋巴瘤相互作用由干扰素γ(CD4+恶性T细胞)和IL-6(活化粒细胞)的正性自调节细胞因子环路介导,最终诱导两类细胞广泛的JAK活化(JAK1/2/3和TYK2)。
- 通过抗体(Ly6G)、遗传性粒细胞清除(LyzM-Cre/MCL1flox/flox)或微环境细胞IL-6缺失阻断炎症症状、减少淋巴瘤浸润并提高小鼠生存。
- 非选择性JAK抑制剂鲁索替尼抑制多种PTCL小鼠模型的TCL进展和粒细胞活化。
临床怎么用
- 原文结论支持广泛JAK抑制作为早期疾病阶段的有效治疗策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Peripheral T-cell lymphomas (PTCLs), especially angioimmunoblastic and follicular TCLs, have a dismal prognosis because of the lack of efficient therapies, and patients' symptoms are often dominated by an inflammatory phenotype, including fever, night sweats, weight loss, and skin rash. In this study, we investigated the role of inflammatory granulocytes and activated cytokine signaling on T-cell follicular helper-type PTCL (TFH-PTCL) disease progression and symptoms. We showed that ITK-SYK-driven murine PTCLs and primary human TFH-PTCL xenografts both induced inflammation in mice, including murine neutrophil expansion and massive cytokine release. Granulocyte/lymphoma interactions were mediated by positive autoregulatory cytokine loops involving interferon gamma (CD4+ malignant T cells) and interleukin 6 (IL-6; activated granulocytes), ultimately inducing broad JAK activation (JAK1/2/3 and TYK2) in both cell types. Inflammatory granulocyte depletion via antibodies (Ly6G), genetic granulocyte depletion (LyzM-Cre/MCL1flox/flox), or IL-6 deletion within microenvironmental cells blocked inflammatory symptoms, reduced lymphoma infiltration, and enhanced mouse survival. Furthermore, unselective JAK inhibitors (ruxolitinib) inhibited both TCL progression and granulocyte activation in various PTCL mouse models. Our results support the important role of granulocyte-driven inflammation, cytokine-induced granulocyte/CD4+ TCL interactions, and an intact JAK/STAT signaling pathway for TFH-PTCL development and also support broad JAK inhibition as an effective treatment strategy in early disease stages.
引用
- Jaeger A, Gambheer SMM, Sun X, et al. Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms. Blood. 2023. PMID: 36696631. doi:10.1182/blood.2022015653
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。